Soluble ST2 has a prognostic role in patients with suspected sepsis.
BACKGROUND
Soluble suppression of tumorigenicity 2 (sST2) has emerged as a novel biomarker for heart failure, and serum sST2 concentrations could be increased in inflammatory diseases. We explored whether sST2 is related to cardiac dysfunction/failure and has a prognostic role in patients with suspected sepsis.


METHODS
In a total of 397 patients with suspected sepsis, sST2 concentrations were measured by using the Presage ST2 Assay (Critical Diagnostics, USA). sST2 concentrations were analyzed according to procalcitonin (PCT) concentrations, cardiovascular subscores of the sepsis-related organ failure assessment (SOFA) score, and clinical outcomes.


RESULTS
sST2 concentrations were increased significantly according to the five groups of PCT concentrations and cardiovascular subscores of the SOFA score (P<0.000001 and P=0.036, respectively). In-hospital mortality was significantly higher among patients with sST2 concentrations above 35 ng/mL (P=0.0213) and among patients with increased concentrations of both sST2 and PCT (P=0.0028).


CONCLUSIONS
sST2 seems to be related to both cardiac dysfunction/failure and severity in sepsis. Measurement of sST2 and PCT in combination would be useful for risk stratification and prognosis prediction in patients with suspected sepsis.
Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea.
Mina
M
Hur
Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea.
Hanah
H
Kim
Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, Korea.
Hyun Jeong
HJ
Kim
Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea.
Hyun Suk
HS
Yang
Department of Medical-Surgery Sciences and Translational Medicine, School of Medicine and Psychology, 'Sapienza' University, Sant' Andrea Hospital, Rome, Italy.
Laura
L
Magrini
Department of Medical-Surgery Sciences and Translational Medicine, School of Medicine and Psychology, 'Sapienza' University, Sant' Andrea Hospital, Rome, Italy.
Rossella
R
Marino
Department of Clinical and Molecular Medicine, School of Medicine and Psychology, 'Sapienza' University, Sant' Andrea Hospital, Rome, Italy.
Patrizia
P
Cardelli
Department of Medical-Surgery Sciences and Translational Medicine, School of Medicine and Psychology, 'Sapienza' University, Sant' Andrea Hospital, Rome, Italy. salvatore.disomma@uniroma1.it.
Salvatore
S
Di Somma
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D002116:Calcitonin / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D000072179:Interleukin-1 Receptor-Like 1 Protein / Q000097:blood*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D011933:Reagent Kits, Diagnostic; D018805:Sepsis / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D055815:Young Adult
D015415:Biomarkers; C079241:IL1RL1 protein, human; D000072179:Interleukin-1 Receptor-Like 1 Protein; D011933:Reagent Kits, Diagnostic; D002116:Calcitonin
Procalcitonin; Prognosis; Sepsis; Soluble suppression of tumorigenicity 2